What does it mean to compare two stocks like Oscar Health and Upstart on a single page?

A stock comparison aligns each company’s business model, financial metrics, and market context side by side. It highlights how Oscar Health and Upstart generate revenue, manage costs, and face industry risks. The aim is to help readers understand differences in strategy, financial health, and growth potential without implying any investment action.

How should I read the pros and cons for each stock?

Pros and cons summarise expected strengths and potential risks from the provided context. For example, Oscar Health’s growth and efficiency are positives, while its losses and volatility are downsides. Upstart’s AI platform is a strength, whereas regulatory or macro risks may temper its outlook. These points aid comparison and context-building.

What market factors influence both Oscar Health and Upstart?

Both stocks operate in sectors affected by macroeconomic conditions, including interest rates and healthcare or lending demand. Regulatory scrutiny can shape performance, while technology-driven business models may magnify volatility. The broader market environment often drives investor sentiment and valuation moves for both names.

How does revenue growth relate to profitability in this comparison?

Revenue growth reflects top-line expansion, a feature for both stocks. However, profitability concerns arise when costs outpace revenue, as seen with Oscar Health's ongoing losses. Upstart’s growth may align with margins if unit economics scale, but profitability is not guaranteed amid market or regulatory challenges.

What role does risk play when evaluating these two stocks?

Risk encompasses volatility, regulatory exposure, and sensitivity to macro conditions. Oscar Health shows a higher beta, indicating greater price swings, while Upstart faces regulatory and demand-cycle risks. Understanding these risks helps calibrate how each stock might respond to market news or policy shifts.

Why might analysts’ price targets differ from current prices for these stocks?

Analysts weigh growth prospects, margins, and risk factors differently, leading to varied price targets. For Oscar Health, some targets could imply downside even amid growth expectations due to losses. For Upstart, targets reflect views on platform scalability and regulatory risk. Market price often reflects new information quickly.

Which metrics should a beginner focus on when reading this page?

Begin with revenue growth, profitability signals (earnings, margins), and cost efficiency (SG&A ratio). Then consider volatility (beta) and any regulatory or legal concerns. This combination helps readers assess growth potential against risk, without relying solely on price movements.

How do business models affect long-term outlook in this comparison?

Oscar Health relies on technology and data to manage costs and member experience, influencing cash burn and expansion pace. Upstart leverages an AI-driven lending platform with scalable margins but faces macro and regulatory headwinds. Business model differences shape resilience to cycles and capital needs.

What does the context say about how to interpret the numbers?

The context presents qualitative and quantitative signals: growth rates, efficiency measures, profitability status, and risk flags. Use them as lenses rather than verdicts. Numbers tell a part of the story; policy, competition, and consumer demand also influence outcomes over time.

How should I treat high volatility when comparing these stocks?

Higher volatility suggests greater potential price swings. For Oscar Health, a beta above 1.8 indicates amplified moves. Upstart may also experience swings due to growth expectations and regulatory considerations. Consider the volatility alongside your risk tolerance and investment horizon.

What educational takeaway does this page aim to provide?

The page offers neutral, accessible information to help readers understand how Oscar Health and Upstart operate and compete. It explains core concepts, key metrics, and market context without advising on buy or sell decisions, emphasising educational purposes and informed comparison.

Oscar Health vs Upstart

상장 기업 vs 대출 신청자와 은행 파트너를 연결하는 AI 대출 플랫폼. 9월 2026에 내 포트폴리오에 더 잘 맞는 종목은 무엇일까요? 아래에서 쉽게 설명합니다.

Oscar Health sells individual and small-group health insurance plans powered by its own technology platform while Upstart uses AI to underwrite personal and auto loans at a pace that traditional lenders can't match, pairing two data-driven financial platforms that took very different paths through the rising-rate environment. Both companies raised capital aggressively during low-rate conditions and had to reckon sharply with investor skepticism when macro conditions shifted. Oscar Health vs Upstart lays out the loss ratio trends, unit economics evolution, and path to sustainable profitability that define whether either company's growth thesis has actually matured.

Oscar Health sells individual and small-group health insurance plans powered by its own technology platform while Upstart uses AI to underwrite personal and auto loans at a pace that traditional lende...

비교 요약

주요 재무 지표

OSCR

지표

UPST

$10.11B

시가총액

$2.49B

-23.50%

예상 수익

67.75%

보유

애널리스트 평가

매수

더 많은 비교 보기

Oscar Health vs Selective

Oscar Health bets its future on tech-driven health insurance for individuals while Selective Insurance has spent over a century quietly compounding in the commercial property-casualty market. Both operate within the broader insurance industry, but their risk profiles, customer bases, and growth trajectories are miles apart. The Oscar Health vs Selective comparison reveals which insurer delivers more compelling financials and whether Oscar's disruptive model can match Selective's proven underwriting discipline.

Oscar Health vs Lemonade

Oscar Health built a tech-forward health insurance platform targeting individual and small-group markets with a digital-first member experience, while Lemonade set out to reinvent property and casualty insurance with AI-driven claims processing and a B-Corp charitable giving model. Both are insurtech companies that raised enormous amounts of capital on the promise that technology could make insurance faster, cheaper, and less adversarial, yet both have faced hard questions about underwriting losses and the path to profitability. The Oscar Health vs Lemonade comparison puts two high-profile insurance disruptors side by side to see whose loss ratios, growth rates, and capital runway tell a more convincing story about eventual viability.

Oscar Health vs Lazard

Oscar Health is a tech-driven health insurer chasing profitability in the individual market, while Lazard is a century-old financial advisory firm monetizing relationships at the top of global M&A and restructuring. They're both navigating fee-intensive business models, but that's where the similarities end. The Oscar Health vs Lazard comparison breaks down how growth trajectory, margin structure, and revenue predictability differ across these two distinct financial services plays.

투자 분석

Oscar Health

OSCR

장점

Oscar Health has demonstrated strong revenue growth, with analysts forecasting a 12.5% annual increase through 2027.
The company achieved record membership growth and improved operational efficiency, with its lowest SG&A ratio in history.
Oscar Health leverages technology and data analytics to enhance member experience and maintain disciplined medical cost management.

고려 사항

Oscar Health continues to report net losses, with negative earnings per share and a negative price-to-earnings ratio.
Analyst consensus and price targets suggest significant downside, with average targets well below current market price.
The stock exhibits high volatility, with a beta above 1.8, indicating greater risk compared to the broader market.

Upstart

UPST

장점

Upstart has established a leading AI-driven lending platform, enabling banks to improve credit decisioning and reduce defaults.
The company has shown strong revenue growth, driven by expanding partnerships and increasing loan volume through its platform.
Upstart maintains a scalable business model with high gross margins and limited direct credit risk exposure.

고려 사항

Upstart's financial performance is highly sensitive to macroeconomic conditions and interest rate fluctuations.
The company has faced regulatory scrutiny and legal challenges related to its lending algorithms and compliance practices.
Upstart's stock has experienced significant volatility and valuation swings, reflecting uncertainty in its growth trajectory.

Oscar Health 및 Upstart 소개

Oscar Health (OSCR)

Oscar Health, Inc. is a healthcare technology company built around a full-stack technology platform. The Company serves individuals, families, and employees through the Patient Protection and Affordable Care Act (ACA). It also offers health technology solutions that power the healthcare industry through +Oscar. It also wholly owns three businesses operating in the individual market: Lucie, Inc., a technology enrollment platform for consumers, employers and brokers; Trove Group Inc., an insurance agency that sells individual medical and supplemental health products, and HealthInsurance.org, LLC, a lead generation website providing educational content to help consumers navigate health insurance as well as the ACA and Medicare marketplaces.

Upstart (UPST)

Upstart Holdings (UPST)는 대출 신청자와 은행을 연결하고 자체적으로 대차대조표에 보유하는 대출도 제공하는 기술 기반 대출 플랫폼을 운영합니다. 회사는 머신러닝 모델을 활용해 신용도를 평가하고 전통적인 FICO 점수를 넘어서는 심사 신호를 중시함으로써, 연체 및 부도 위험을 관리하는 동시에 승인율을 높이는 것을 목표로 합니다. 매출은 대출 취급 및 관리 수수료, 보유 대출에서 발생하는 이자수익, 은행 파트너로부터 받는 플랫폼 수수료에서 발생합니다. 투자자는 신용 사이클, 모델 성능과 데이터 드리프트, 조달 비용, 알고리즘 대출과 관련한 규제 당국의 잠재적 조사에 대한 민감도를 유의해야 합니다. Upstart는 빠른 성장과 높은 변동성이 나타난 시기를 경험했으며, 향후 수익성은 대손상각, 대출 규모와 자금 조달 여건에 좌우됩니다. 이는 일반적인 교육 목적의 정보이며 개인 맞춤형 투자 조언이 아닙니다. 투자금의 가치는 상승할 수도 하락할 수도 있으며 과거 실적이 미래 성과를 보장하지 않습니다.

어떤 바스켓에 포함되어 있나요?

Medicare Advantage Rate Hike Opportunities in 2026

The Centers for Medicare & Medicaid Services finalized a 2.48% payment increase for 2027, granting health insurers a surprise $13 billion funding boost. This collection features managed care organizations and healthcare providers poised to benefit from this highly favorable regulatory reversal.

게시일: 2026년 4월 10일

바스켓 살펴보기